"egfr tyrosine kinase inhibitors" trang 5 - tải miễn phí từ tailieunhanh
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: A case report

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: A case report
6    47    0
Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
9    81    1
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study
11    41    0
Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
7    77    1
Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study

Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study
8    59    1
Case report: Primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

Case report: Primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
4    42    1
Đột biến EGFR-T790M liên quan đến kháng thuốc ức chế tyrosine kinase ở bệnh nhân ung thư phổi không tế bào nhỏ

Đột biến EGFR-T790M liên quan đến kháng thuốc ức chế tyrosine kinase ở bệnh nhân ung thư phổi không tế bào nhỏ
9    56    1
Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients

Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients
6    56    1
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer
11    51    1
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
10    36    1
The expression and prognostic value of the epidermal growth factor receptor family in glioma

The expression and prognostic value of the epidermal growth factor receptor family in glioma
14    42    1
Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: A case report

Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: A case report
4    26    1
Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment

Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment
7    24    1
Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: A propensity-matched retrospective study

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: A propensity-matched retrospective study
10    17    1
A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer
8    28    1
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: A prospective and single arm study (DANCE study)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: A prospective and single arm study (DANCE study)
6    20    1
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study
11    4    1
Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: A retrospective study

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: A retrospective study
9    5    1
Điều trị bước một thuốc ức chế Tyrosine kinase trong ung thư phổi không tế bào nhỏ giai đoạn tiến xa có đột biến EGFR

Điều trị bước một thuốc ức chế Tyrosine kinase trong ung thư phổi không tế bào nhỏ giai đoạn tiến xa có đột biến EGFR
8    1    1
The performance of NLST screening criteria in Asian lung cancer patients

The performance of NLST screening criteria in Asian lung cancer patients
6    44    1